Categories: CancerNewsNursing

Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis

NORTHAMPTON, MA / ACCESSWIRE / June 5, 2024 / Emma was a 28-year-old nursing student when she was diagnosed with triple-negative breast cancer. She had always wanted children and, once she learned that her treatment could affect her fertility, she found herself needing to make a quick family planning decision to pursue in vitro fertilization (IVF) and freeze her eggs.

“You think that you have time to have all these things happen, and you don’t,” says Emma. “Your life is put on hold and your future’s put on hold, and who knows if you even could have kids.”

According to the National Breast Cancer Foundation, about 9% of women diagnosed with breast cancer in the United States are younger than 45 years old. While surgery and radiation rarely affect fertility, women who undergo chemotherapy can experience immediate or long-term infertility if eggs become damaged or destroyed. Other cancer treatments, such as hormone therapy, aren’t known to cause infertility, but the treatment duration could interfere with the biological clock of childbearing years.

Gilead partners with various organizations that support people living with breast cancer. One such organization, the Young Survival Coalition (YSC), recognizes the unique needs of people of childbearing age and works with patients under 40 through nearly every facet of their cancer treatment journey.

“People may tell you to focus on treating your cancer first, but it’s important that you also consider life after cancer treatment and the impact of any treatment you may choose,” says Amanda Nixon, YSC’s Director of Community Engagement and Empowerment. She says her organization always recommends that younger women diagnosed with cancer seek a consultation from a fertility preservation expert if having biological children is of interest.

Watch the video above to learn about two women’s fertility journey.

Originally published by Gilead Sciences

View additional multimedia and more ESG storytelling from Gilead Sciences on 3blmedia.com.

Contact Info:
Spokesperson: Gilead Sciences
Website: https://www.3blmedia.com/profiles/gilead-sciences
Email: info@3blmedia.com

SOURCE: Gilead Sciences

View the original press release on accesswire.com

Staff

Recent Posts

Vent Creativity Appoints Paul Abrams as Vice President of Sales to Lead Commercial Growth

NEW YORK--(BUSINESS WIRE)--Vent Creativity, a medical technology company advancing AI-enabled surgical planning, today announced the…

3 hours ago

AEON Clinic Announces Next Generation Medicine Congress 2026 Event: A Global Convergence on Human Longevity in Dubai

AEON Clinic Elevates Dubai to Global Hub for Longevity Science, A Definitive Four-Day Summit Defining…

3 hours ago

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

1 day ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

1 day ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

1 day ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

1 day ago